查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585617

生物工程蛋白藥物市場：按藥物類型、疾病和最終用戶分類 - 全球預測 2025-2030

Bioengineered Protein Drugs Market by Drug Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), Disease (Arthritis, Autoimmune Disorders, Blood Disorders), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

生物工程蛋白藥物市場2023年估值為3,870.3億美元，預計到2024年將達到4,151.3億美元，複合年成長率為7.76%，到2030年將達到6533.5億美元。

生物工程蛋白質藥物，也稱為生技藥品，是指透過重組DNA技術製造的治療性蛋白質，對於治療多種疾病至關重要，包括癌症、糖尿病和自體免疫疾病。他們的需求源自於他們能夠高精度地針對特定途徑，描述傳統小分子藥物無法滿足的治療選擇。它具有單株抗體、疫苗和荷爾蒙治療等應用，並具有廣泛的最終用途，包括醫院、診所和研究機構。該市場受到多種因素的影響，包括慢性病的流行、基因和蛋白質工程的技術進步以及支持性的政府法規。越來越多的老年人和醫療保健提供者對生技藥品認知的提高進一步推動了需求。潛在的機會包括擴展到獲得先進治療方法有限的新興市場，以及使產品系列多樣化以包括個人化醫療方法。生技公司之間的策略聯盟增強了研發能力，實現了突破性創新和快速商業化。然而，挑戰包括高昂的開發成本、複雜的製造流程、嚴格的監管要求以及來自生物相似藥的競爭。此外，市場成長受到價格壓力和專利到期的限制。對於業務成長而言，重點關注藥物輸送系統和生物加工技術的創新以提高產品功效和患者依從性非常重要。開拓具有成本效益且可靠的生物相似藥可以在專利到期後佔領市場佔有率。此外，在藥物開發和患者選擇中探索人工智慧和機器學習可以完善治療應用。該市場的特點是技術快速發展和研發方面的大量投資，凸顯了持續創新的需求。公司透過採用資料主導的決策並積極參與策略聯盟來確保生物工程蛋白藥物領域的持續成長，以保持競爭優勢並捕捉新興市場趨勢。

主要市場統計
基準年[2023] 3870.3億美元
預測年份 [2024] 4151.3億美元
預測年份 [2030] 6533.5億美元
複合年成長率（%） 7.76%

市場動態：揭示快速發展的生物工程蛋白質藥物市場的關鍵市場洞察

生物工程蛋白質藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 人口中慢性病盛行率上升
    • 提高醫療意識和生物工程蛋白藥物的巨大好處
    • 各國醫療支出增加
  • 市場限制因素
    • 與生物工程蛋白質藥物相關的高成本
  • 市場機會
    • 活性化新生物工程蛋白藥物的開發與引進研究活動
    • 奈米技術在大分子遞送的新應用
  • 市場問題
    • 核准過程艱難且漫長

波特五力：駕馭生物工程蛋白藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生物工程蛋白藥物市場的外部影響

外部宏觀環境因素在塑造生物工程蛋白藥物市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解生物工程蛋白質藥物市場的競爭格局

對生物工程蛋白藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生物工程蛋白藥物市場供應商的績效評估

FPNV 定位矩陣是評估生物工程蛋白藥物市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：在生物工程蛋白藥物市場中製定成功之路

對於旨在加強其在全球市場的影響力的公司來說，對生物工程蛋白藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口中慢性病盛行率不斷上升
      • 提高醫療意識和生物工程蛋白藥物的巨大好處
      • 各國醫療費用支出增加
    • 抑制因素
      • 與生物工程蛋白質藥物相關的高成本
    • 機會
      • 擴大新生物工程蛋白質藥物開發與引進的研究活動
      • 奈米技術在大分子遞送的新應用
    • 任務
      • 嚴格而漫長的核准流程
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章生物工程蛋白藥物市場：依藥物類型

  • 介紹
  • 單株抗體
  • 治療性蛋白質
  • 疫苗

第7章生物工程蛋白藥物市場：依疾病分類

  • 介紹
  • 關節炎
  • 自體免疫疾病
  • 血液疾病
  • 癌症
  • 先天性疾病
  • 心臟病
  • 感染疾病
  • 神經退化性疾病
  • 呼吸系統疾病
  • 皮膚病

第8章生物工程蛋白質藥物市場：依最終用戶分類

  • 介紹
  • CRO
  • 製藥和生物技術公司
  • 研究所

第9章美洲生物工程蛋白藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太生物工程蛋白藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲生物工程蛋白藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Ambrx, Inc.
  • AMGEN INC.
  • Aravive, Inc.
  • Astrazeneca PLC
  • Baxter Healthcare
  • Bayer Pharmaceuticals
  • BRISTOL-MYERS SQUIBB
  • CSL LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GRIFOLS SA
  • Hoffman-la-Roche
  • MERCK & CO., INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • PFIZER INC.
  • Polaris Group
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO., LTD.
Product Code: MRR-69324464D0EE

The Bioengineered Protein Drugs Market was valued at USD 387.03 billion in 2023, expected to reach USD 415.13 billion in 2024, and is projected to grow at a CAGR of 7.76%, to USD 653.35 billion by 2030.

Bioengineered protein drugs, also known as biologics, refer to therapeutic proteins created through recombinant DNA technology and are essential for treating various diseases such as cancer, diabetes, and autoimmune disorders. Their necessity stems from their ability to target specific pathways with high precision, offering treatment options where traditional small-molecule drugs fall short. Applications include monoclonal antibodies, vaccines, and hormone treatments, with end-use spanning hospitals, clinics, and research institutions. The market is influenced by several factors, such as increasing prevalence of chronic diseases, technological advancements in genetic and protein engineering, and supportive government regulations. A growing geriatric population and heightened awareness of biologics among healthcare providers further drive demand. Potential opportunities include expanding into emerging markets with limited access to advanced therapeutics and diversifying product portfolios to include personalized medicine approaches. Strategic alliances between biotech firms can enhance R&D capabilities, enabling breakthrough innovations and faster commercialization. However, challenges such as high development costs, complex manufacturing processes, stringent regulatory requirements, and competition from biosimilars pose limitations. Additionally, market growth is constrained by pricing pressures and patent expirations. For business growth, focusing on innovations in drug delivery systems and bioprocessing technologies to improve product efficacy and patient compliance is crucial. Developing biosimilars with cost-effectiveness and reliability can capture market share post-patent expiration. Furthermore, exploring artificial intelligence and machine learning in drug development and patient selection can refine therapeutic applications. The market is characterized by rapid technological evolution and significant investment in research and development, underscoring the need for continuous innovation. Companies should employ data-driven decision-making and actively engage in strategic collaborations to maintain competitive advantage and capture emerging market trends, thereby ensuring sustained growth in the bioengineered protein drugs sector.

KEY MARKET STATISTICS
Base Year [2023] USD 387.03 billion
Estimated Year [2024] USD 415.13 billion
Forecast Year [2030] USD 653.35 billion
CAGR (%) 7.76%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bioengineered Protein Drugs Market

The Bioengineered Protein Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases among population
    • Growing healthcare awareness and significant benefits of bioengineered protein drugs
    • Increase in healthcare spending across economies
  • Market Restraints
    • High costs associated with the bioengineered protein drugs
  • Market Opportunities
    • Growing research activities to develop and introduce novel bioengineered protein drugs
    • Emerging applications of nanotechnology in macromolecules delivery
  • Market Challenges
    • Stringent and time consuming approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Bioengineered Protein Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bioengineered Protein Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bioengineered Protein Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bioengineered Protein Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bioengineered Protein Drugs Market

A detailed market share analysis in the Bioengineered Protein Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bioengineered Protein Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bioengineered Protein Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bioengineered Protein Drugs Market

A strategic analysis of the Bioengineered Protein Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bioengineered Protein Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambrx, Inc., AMGEN INC., Aravive, Inc., Astrazeneca PLC, Baxter Healthcare, Bayer Pharmaceuticals, BRISTOL-MYERS SQUIBB, CSL LTD., F. HOFFMANN-LA ROCHE AG, GLAXOSMITHKLINE PLC, GRIFOLS S.A., Hoffman-la-Roche, MERCK & CO., INC., NOVARTIS AG, NOVO NORDISK A/S, PFIZER INC., Polaris Group, REGENERON PHARMACEUTICALS INC., SANOFI, and TAKEDA PHARMACEUTICAL CO., LTD..

Market Segmentation & Coverage

This research report categorizes the Bioengineered Protein Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Monoclonal Antibodies, Therapeutic Proteins, and Vaccines.
  • Based on Disease, market is studied across Arthritis, Autoimmune Disorders, Blood Disorders, Cancer, Congenital Diseases, Heart Diseases, Infectious Diseases, Neurodegenerative Diseases, Respiratory Diseases, and Skin Diseases.
  • Based on End-User, market is studied across CROs, Pharmaceutical and Biotechnology Companies, and Research institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among population
      • 5.1.1.2. Growing healthcare awareness and significant benefits of bioengineered protein drugs
      • 5.1.1.3. Increase in healthcare spending across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the bioengineered protein drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research activities to develop and introduce novel bioengineered protein drugs
      • 5.1.3.2. Emerging applications of nanotechnology in macromolecules delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and time consuming approval processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bioengineered Protein Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Therapeutic Proteins
  • 6.4. Vaccines

7. Bioengineered Protein Drugs Market, by Disease

  • 7.1. Introduction
  • 7.2. Arthritis
  • 7.3. Autoimmune Disorders
  • 7.4. Blood Disorders
  • 7.5. Cancer
  • 7.6. Congenital Diseases
  • 7.7. Heart Diseases
  • 7.8. Infectious Diseases
  • 7.9. Neurodegenerative Diseases
  • 7.10. Respiratory Diseases
  • 7.11. Skin Diseases

8. Bioengineered Protein Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. CROs
  • 8.3. Pharmaceutical and Biotechnology Companies
  • 8.4. Research institutes

9. Americas Bioengineered Protein Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bioengineered Protein Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bioengineered Protein Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Ambrx, Inc.
  • 3. AMGEN INC.
  • 4. Aravive, Inc.
  • 5. Astrazeneca PLC
  • 6. Baxter Healthcare
  • 7. Bayer Pharmaceuticals
  • 8. BRISTOL-MYERS SQUIBB
  • 9. CSL LTD.
  • 10. F. HOFFMANN-LA ROCHE AG
  • 11. GLAXOSMITHKLINE PLC
  • 12. GRIFOLS S.A.
  • 13. Hoffman-la-Roche
  • 14. MERCK & CO., INC.
  • 15. NOVARTIS AG
  • 16. NOVO NORDISK A/S
  • 17. PFIZER INC.
  • 18. Polaris Group
  • 19. REGENERON PHARMACEUTICALS INC.
  • 20. SANOFI
  • 21. TAKEDA PHARMACEUTICAL CO., LTD.

LIST OF FIGURES

  • FIGURE 1. BIOENGINEERED PROTEIN DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOENGINEERED PROTEIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOENGINEERED PROTEIN DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CONGENITAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEART DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 154. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023